STIPE Therapeutics ApS: Financial statements 2023
CVR: 39691175
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
STIPE Therapeutics ApS (CVR 39691175) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR -3,456,557 and a net result of EUR -4,456,130 compared with EUR -8,272,781 the year before. Equity in the 2023 report amounted to EUR -2,497,024. The company had 14 employees in the financial year.
- Gross Profit
- EUR -3,456,557
- Profit/Loss
- EUR -4,456,130
- Equity
- EUR -2,497,024
- Total Assets
- EUR 3,217,612
- Employees
- 14
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -3.5 mio. EUR | -4.5 mio. EUR | -2.5 mio. EUR | 14 |
| 2022 | - | -6.6 mio. EUR | -8.3 mio. EUR | 2 mio. EUR | 16 |
| 2021 | - | -4.1 mio. EUR | -5.5 mio. EUR | 10.2 mio. EUR | 16 |
| 2020 | - | -2.9 mio. EUR | -3.9 mio. EUR | 3.8 mio. EUR | 14 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of December 31, 2023, Natalie Rose Sacks has left the board of directors of STIPE Therapeutics ApS.
As of September 14, 2023, Mark David Chin has left the board of directors of STIPE Therapeutics ApS.
As of September 12, 2023, Novo Holdings A/S is registered as an owner of STIPE Therapeutics ApS with an ownership share of 25%.
As of September 8, 2023, Sunstone Life Science Ventures Fund IV K/S is registered as an owner of STIPE Therapeutics ApS with an ownership share of 20%.
As of September 5, 2023, is registered as an owner of STIPE Therapeutics ApS with an ownership share of 20%.
STIPE Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -6,587,704, and the net result was DKK -8,272,781.
About STIPE Therapeutics ApS
STIPE Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company's owners include CLAUS OLESEN HOLDING ApS, Novo Holdings A/S and Sunstone Life Science Ventures Fund IV K/S. The company has 5 employees (2018). In 2024, the company reported a gross profit of EUR -842,285 and a net result of EUR 1,448,748 compared with EUR -4,456,130 the year before. Equity in the 2024 report amounted to EUR 1,087,512.